Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 5/20 | 0.43 |
| ▸ | CASR | P41180 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | THRA | P10827 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1744713 | 0.88 | PIN1 (0.40) | FFAR1CASRIDO1PIN1 | |
| SCHEMBL6062696 | 0.86 | FFAR1 (0.43) | FFAR1CASRFFAR4IDO1RXRA | |
| SCHEMBL1633343 | 0.81 | FFAR1 (0.57) | FFAR1FFAR4KEAP1 | |
| SCHEMBL1633344 | 0.81 | FFAR1 (0.57) | FFAR1FFAR4KEAP1 | |
| SCHEMBL1745432 | 0.81 | FFAR1 (0.57) | FFAR1FFAR4KEAP1 | |
| SCHEMBL12320178 | 0.78 | IDO1 (0.51) | FFAR1IDO1PIN1 | |
| SCHEMBL1745540 | 0.77 | FFAR4 (0.44) | FFAR1FFAR4 | |
| SCHEMBL15679184 | 0.77 | FFAR1 (0.42) | FFAR1FFAR4IDO1RXRARXRB | |
| SCHEMBL4261413 | 0.77 | CCR2 (0.42) | FFAR1IDO1PIN1 | |
| SCHEMBL4261410 | 0.77 | CCR2 (0.42) | FFAR1IDO1PIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080167378-A1 | Receptor Function Regulation Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | US | claimed |
| EP-1688138-A1 | RECEPTOR FUNCTION REGULATING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2006-08-09 | — | — | EP | claimed |
| EP-1559422-B1 | RECEPTOR FUNCTION CONTROLLING AGENT | TAKEDA PHARMACEUTICAL (JP) | 2014-04-30 | — | — | EP | disclosed |
| EP-1559422-B1 | RECEPTOR FUNCTION CONTROLLING AGENT | TAKEDA PHARMACEUTICAL (JP) | 2014-04-30 | — | — | EP | disclosed |
| EP-2385032-A1 | GPR40 Receptor function regulator | Takeda Pharmaceutical Company Limited (JP) | 2011-11-09 | — | — | EP | disclosed |
| EP-2385032-A1 | GPR40 Receptor function regulator | Takeda Pharmaceutical Company Limited (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-8008525-B2 | For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-30 | — | — | US | disclosed |
| US-7960369-B2 | Receptor function regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-7960369-B2 | Receptor function regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-7960369-B2 | Receptor function regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090012093-A1 | Receptor Function Regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| US-20090012093-A1 | Receptor Function Regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| US-20090012093-A1 | Receptor Function Regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| US-20080167378-A1 | Receptor Function Regulation Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | US | disclosed |
| EP-1688138-A1 | RECEPTOR FUNCTION REGULATING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2006-08-09 | — | — | EP | disclosed |
| EP-1559422-A1 | RECEPTOR FUNCTION CONTROLLING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167378-A1 | Receptor Function Regulation Agent | GPR119, INSR, GPR88 | FFAR1 16/4885CASR 49/4885FFAR4 17/4885 |
| US-20090012093-A1 | Receptor Function Regulator | GPR119, GIPR, INSR | FFAR1 33/4885CASR 63/4885FFAR4 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.